Publications
3-Years follow-up results of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus Debio 1143 (xevinapant) or placebo in…
Safety and efficacy of Xevinapant (Debio 1143), an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in…
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind,…
Debio 1143 Mode of Action: a Broad Chemo-Radio and Immuno-Therapy Sensitizer
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…
Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF-alpha-mediated in head and neck squamous cell carcinoma.